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Abstract HT-29 sublines and Caco-2 clones were analyzed for the expression of cytochrome P-450 3A. The enzyme was found to be expressed in 
differentiated HT-29 cells selected by resistance to methotrexate and in one of seven Caco-2 clones, TC7. Its expression parallels the differentiation 
process, with highest levels being observed at late contluency. P-450 3A mRNA and protein patterns, as well as subcellular distribution, are 
intermediate between those observed in human adult intestine and fetal liver. 
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1. Introduction 
The cytochrome P-450 gene superfamily [l] encodes 
monooxygenases playing a major role in the metabolism of 
xenobiotics. Although the liver is generally the organ with the 
highest xenobiotic-metabolizing activity, P-450~ are also pres- 
ent in other tissues, including the intestinal epithelium [2,12]. 
Most studies concerning intestinal P-450~ have been performed 
in animal models [4-61. In man, the major P45Os found in the 
small intestine belong to the CYF3A subfamily [7-121 and in- 
clude CYF3A4 [l l] and CYF3A5 [12]. Although considerable 
progress has been made in the knowledge of the transduction 
pathways involved in the transcriptional regulation of some 
P-450 genes like IA and 2E [13-151, little is known of the 
regulation mechanisms which control intestinal CYP3A expres- 
sion. One main reason to this situation is the lack of availability 
of reproducible in vitro models. The purpose of the present 
work was therefore to investigate whether differentiated popu- 
lations isolated from the human colon carcinoma cell lines 
HT-29 and Caco-2 would express CYF3A. For this we used 
HT-29 sublines, either obtained by adaptation to hexose-free 
medium, which express an enterocytic phenotype [16] or se- 
lected by increasing concentrations of methotrexate (MTX) 
[17]. These latter cells, which form a mixed population of goblet 
cells and enterocytes when adapted to MTX lo-’ M, of goblet 
cells exclusively at 10e6 M, and of enterocyte-like cells at 10V3 
M [17], maintain their differentiation characteristics when fur- 
ther subcultured in drug-free medium [17]. We also used 7 
clones isolated from the Caco-2 cell line [18]. These clones all 
display an enterocytic differentiation but differ one from an- 
other as to the level of expression of membrane proteins in- 
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Abbreviations: MTX, methotrexate; CYP3A, cytochrome P-450 3A, 
named according to recent recommendations for standardization of 
P-450 gene nomenclature [l]; DPP-IV, dipeptidylpeptidase-IV; SI, su- 
erase-isomaltase. 
volved in glucose utilization, namely sucrase-isomaltase and 
hexose transporters [18,19]. 
2. Materials and methods 
HT-29 populations included parental cells, referred to as HT-29, cells 
resistant o MTK lo-‘, 10m6 and 10e3 M, referred to as HT2PMTX 
IO-“, and cells adapted to glucose-free medium [16] and reversed to 
standard culture conditions, referred to as HT29-RevGlc-. Clones PD7, 
PDlO, PFll, TBlO, TC7, TF3 and TG6, were isolated from early and 
late passages of Caco-2 cells as reported [18]. Culture conditions were 
the same as previously reported for HT-29 [17] and Caco-2 cells [18]. 
Normal adult and fetal tissues were obtained as reported [20]. Double 
labeling immunofluorescence was performed on cryostat sections of 
tissues and cell layer rolls as in [17,18], using mAb K03 against human 
cytochrome P-450 3A [21] and a polyclonal rabbit antiserum against 
villin [22], obtained from D. Louvard (Institut Pasteur, Paris). Western 
blot detection of CYP3A was performed with mAb K03 as in 1211 on 
microsomal proteins from cells and tissues prepared as described [lo]. 
CYP3A4 and CYP3A5 vroteins were vroduced in veast as revorted in 
[23]. Extraction of RNA with guanidium isothiocyanate and’centrifu- 
gation through a CsCl gradient [24], and Northern blot analysis were 
as described previously [18,25]. P-450 3A mRNA was detected using 
cDNA clone nf-25 [26], sucrase-isomaltase with cDNA probe S12 [27], 
obtained from D. Swallow (MRC Human Biochemical Genetics Unit, 
University College, London), and dipeptidylpeptidase-IV with cDNA 
DPI-101 [28]. For quantitation of RNA, membranes were dehybridized 
and stained with Methylene blue. This was preferred to hybridization 
with actin or GAPDH as it was found that the level of these transcripts 
may vary with the phases of cell growth and from one cell line to 
another. 
3. Results 
Based on the growth-related variations of the differentiation 
process, screening of the different cell populations for the pres- 
ence of CYF3A mRNA was performed on late post-confluent 
cells. As shown in Fig. 1, although trace amounts of CYP3A 
mRNA are detectable in most populations, it is present at a 
significant level only in HT29-MTX cells and in the Caco-2 
clone TC7. Comparison with small intestine and fetal liver 
shows that, in HT29-MTX cells, only the 1.9 kb transcript is 
present, whereas TC7 express three transcripts, like in the small 
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Fig. 1. Northern blot analysis of CYP3A in HT-29 subpopulations and Caw-2 clones. Left, upper panel, total RNA from post-confluent cultures 
(day 21) of the indicated cells (20 pg for HT-29 populations, 15 pg for Caeo-2 clones) was hybridized with cDNA nf-25 (CYP3A); lower panel, 
Methylene blue staining of the same dehybridiid membrane. Right, upper panel, the same quantity of total RNA (10 pg) from the indicated cells, 
fetal liver (FL) and ileum (IL) were allowed to migrate for a longer time than in left panel and hybridized with CYP3A probe; FL*, shorter exposure 
time in order to visualize the 1.9 kb transcript; lower panel, Methylene blue staining of 28 S from the same dehybridized membrane. 
intestine and fetal liver. However, the pattern observed in TC7 
cells differs from that observed in intestine and fetal liver with 
the upper band migrating between the 3.1 kb fetal liver and the 
2.8 kb intestinal transcripts (Fig. 1). 
In order to verify whether expression of CYP3A is associated 
with the differentiation process, CYP3A mRNA was analyzed 
at different stages of culture of HT29-MTX 10e6 and TC7 cells, 
in comparison with classical markers of differentiation, namely 
DPP-IV for HT29MTX [17] and sucrase-isomaltase for TC7 
cells [18]. As shown in Fig. 2, there is a concomitant expression 
of CYP3A and differentiation markers, with highest levels 
being observed at late confluency. 
For characterization of CYP3A expression at the protein 
level, HT29-MTX 10d6 and TC7 cells were therefore analyzed 
at late post-confluency. Western blot analysis of cellular micro- 
somal fractions shows that CYP3A from the two populations 
migrates at a level which is intermediate between that observed 
TC7 HT294TX 
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Fig. 2. Growth and differentiation-related expression of CYP3A 
mRNA in Caco-2-TC7 and HT29-MTX 10e6 cells. Total RNA (20 pg) 
from cells harvested at the indicated days of culture was successively 
hybridized with cDNA nf-25 (3A), SI2 (sucrase-isomaltase) or DPI-101 
(DPP-IV), dehybridized and stained with Methylene blue. 
with fetal liver and CYP3A5 protein on one hand and small 
intestine and CYP3A4 on the other hand (Fig. 3). As shown by 
immunofluorescence, CYP3A is diffusely expressed in the cyto- 
plasm of TC7 cells, without apparent polarized compartimen- 
taliiation, as shown by double labeling with villin (Fig. 4). In 
HT29-MTX cells it appears to be localized between the nucleus 
and the mucus compartment (Fig. 4). Although the intensity of 
staining of CYP3A is much lower in the cells than in fetal liver 
or small intestine, the diffuse cytoplasmic distribution observed 
in TC7 cells resembles that in the fetal liver (Fig. 4e). In both 
cell types it differs however from the apical compartmentaliza- 
tion which, as already reported [l 11, is observed in the small 
intestine (Fig. 40. 
-Ml-xl 0-s 
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Fig. 3. Western blot analysis of HT29-MTX lo* and TC7 CYP3A 
isoforms. Microsomal proteins from post-confluent cultures (day 21) 
of the indicated cells (40 pg) were analyzed with mAb K03 in compar- 
ison with microsomal extracts from IL, same normal adult ileum as in 
Fig. 1 (5 p(p), FL, same fetal liver as in Fig. 1 (1 ,ug), CYP3A4 and 
CYP3A5 proteins expressed in yeast (0.1 pmol). 
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Fig. 4. Indirect immunofluorescent s aining of CYPSA in HT29-MTX 
10m6 and TC7 cells. Cryostat sections of postconfluent (day 21) HT29- 
MTX 10e6 (a,b) and TC7 cells (c,d) were double stained with (a,c) mAb 
K03 against CYP3A and rhodamine-labeled anti-globulins and (b,d) 
a polyclonal rabbit antibody against villin, used as a marker of the 
brush border, and fluorescein isothiocyanate-labeled anti-globulins; 
(e) same fetal liver and (f) same adult ileum as in Fig. 1 stained with 
mAb K03. Arrows point to CYP3A, arrow heads to villin, double 
arrow heads in a and b to mucus. Bar, 50 pm. 
Finally, since the expression of CYP3A in the HT-29 popula- 
tions analyzed is mainly associated with HT29-MTX cells, it 
was important to analyze whether this expression is a conse- 
quence of MTX treatment or a specific feature of the selected 
differentiated phenotypes. As shown in Fig. 5, reversion to 
drug-free medium for several passages of HT29-MTX cells has 
no effect on the level of expression of either CYP3A mRNA 
or protein. 
4. Discussion 
We show here that differentiated subpopulations isolated 
from the HT-29 cell line by resistance to methotrexate and 
Caco-2 cell clone TC7 do express CYP3A. Expression of 
CYP3A is closely associated with the differentiation process as 
substantiated by its growth-related appearance and concomi- 
tant expression of differentiation markers, This growth-related 
expression mimics that observed in the small intestine in which 
both mRNA and protein are absent from dividing crypt cells 
and appear when the cells migrate along the crypt-villus axis 
[5,11]. Although expression of CYP3A in HT-29 and Caco-2 
cells is associated with the differentiation of the cells, it is 
independent from the phenotype of differentiation as it is pres- 
ent in mucus-secreting cells, like HT29-MTX 10m6, and in en- 
terocyte-like cells, like HT29MTX 10V3 and Caco-2 clone TC7. 
Conversely, cell differentiation is not sufficient for the expres- 
sion of CYP3A, as it is significantly expressed neither in entero- 
cytic HT29RevGlc- cells, nor in any of the other Caco-2 cell 
clones, although they express the same high degree of entero- 
cytic differentiation as TC7 cells [18]. This would suggest hat 
HT-29 and Caco-2 parental cells contain a minor population 
of cells able to express CYP3A which are selected uring induc- 
tion of MTX resistance of HT-29 cells or cloning of Caco-2 
cells. 
Both HT29-MTX and TC7 cells express a CYP3A mRNA 
transcript of 1.9 kb, a transcript shown to be mainly, but not 
exclusively, associated with fetal liver CYP3A [29]. This tran- 
script is the only one expressed in HT29-MTX cells, thus differ- 
ing from TC7 cells which also express two higher transcripts, 
like in the small intestine and fetal liver, with the upper one 
differing from that observed in these two conditions. At the 
protein level both types of cells express a protein which mi- 
grates at a level intermediate between CYP3A4 and CYP3A5, 
one of the isoforms also found in fetal liver [30]. This finding 
is consistent with the observation that most differentiation fea- 
tures of HT-29 and Caco-2 cells share fetal and adult character- 
istics [3 I]. 
These results are the first to demonstrate that cell lines of 
intestinal origin are able to express CYP3A. In view of the 
observation that the isoform expressed iffers from both 3A4 
and 3A5, further studies should determine whether it is 
CYP3A7 [32-341, a gene also expressed in fetal liver which 
Fig. 5. Permanence of CYP3A expression in HT29-MTX cells reversed 
to drug-free medium. HT29-MTX 10e3 cells, passage 18 (MTX’) were 
subcultured for the indicated number of passages (P) in MTX free 
medium and analyzed at late post-conlluency (day 21). Upper panel, 
total RNA from &lls (20 pg), same IL and FL (5 mg) asin.Pig. 1, 
hvbridiied with cDNA nf-25: middle panel, same membrane dehv- 
bhdixed and stained with Methylene blue; lower panel, Western blot 
analysis of microsomal fractions of the cells (40 pg) and of same prep- 
arations of FL (1 gg) and IL (5 pg) as in Fig. 3. 
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shows 82% of amino acid homology with CYP3AS [35], or a 
still uncharacterized 3A isoform. Whether these cells can be 
helpful models for investigating the regulation mechanisms 
which control CYP3A expression remains to be investigated. 
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